Es gibt sie noch, die 1000% Aktien (siehe Primacom und co.)
Es gibt aber auch noch welche, die stehen grad am Anfang der 1000 Prozent.
Eine dieser Aktien dürfte die amerikanische Neose Technologies Inc. (WKN: 899410).
Dieser Wert hat vor kurzem erst ein Alltime-Low markiert und ist seitdem schon kräftig angezogen. Kursziele von 4,50 Dollar (100 %) dürfte auf kurze Sicht locker drin sein, der Wert könnte aber ohne weiteres bis auf 7 Dollar steigen (siehe W-Formation), wenn dann für die biopharmazeutische Schmiede aus den USA alles nach Plan läuft, können ganz leicht Kurse über der 14 Dollar Marke angepeilt werden!
Homepage des Konzerns: www.neose.com
Text zur Anzeige gekürzt. Gesamtes Posting anzeigen...
Neose is a biopharmaceutical company using its enzymatic technologies to develop proprietary drugs, focusing primarily on therapeutic proteins. We believe that our core enzymatic technologies, GlycoAdvance® and GlycoPEGylation™, improve the drug properties of therapeutic proteins by building out, and attaching polyethylene glycol (PEG) to, carbohydrate structures on the proteins. We are using our technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed by our partners. We expect these modified proteins to offer significant advantages, including less frequent dosing and possibly improved efficacy, over the original versions of the drugs now on the market, as well as to meet or exceed the pharmacokinetic profile of next-generation versions of the drugs now on the market. We believe this strategy of targeting drugs with proven safety and efficacy allows us to lower the risk profile of our proprietary development portfolio as compared to de novo protein drug development.
Our proprietary drug development portfolio currently consists of two therapeutic protein candidates. GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and is approved for sale in major markets around the world for treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Our second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor (G-CSF) that we are co-developing with BioGeneriX AG, a company of the ratiopharm Group. G-CSF is prescribed to stimulate production of neutrophils (a type of white blood cell) and is approved for sale in major markets around the world for treatment of neutropenia associated with myelosuppressive chemotherapy. .
Es gibt aber auch noch welche, die stehen grad am Anfang der 1000 Prozent.
Eine dieser Aktien dürfte die amerikanische Neose Technologies Inc. (WKN: 899410).
Dieser Wert hat vor kurzem erst ein Alltime-Low markiert und ist seitdem schon kräftig angezogen. Kursziele von 4,50 Dollar (100 %) dürfte auf kurze Sicht locker drin sein, der Wert könnte aber ohne weiteres bis auf 7 Dollar steigen (siehe W-Formation), wenn dann für die biopharmazeutische Schmiede aus den USA alles nach Plan läuft, können ganz leicht Kurse über der 14 Dollar Marke angepeilt werden!
Homepage des Konzerns: www.neose.com
Text zur Anzeige gekürzt. Gesamtes Posting anzeigen...
Neose is a biopharmaceutical company using its enzymatic technologies to develop proprietary drugs, focusing primarily on therapeutic proteins. We believe that our core enzymatic technologies, GlycoAdvance® and GlycoPEGylation™, improve the drug properties of therapeutic proteins by building out, and attaching polyethylene glycol (PEG) to, carbohydrate structures on the proteins. We are using our technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed by our partners. We expect these modified proteins to offer significant advantages, including less frequent dosing and possibly improved efficacy, over the original versions of the drugs now on the market, as well as to meet or exceed the pharmacokinetic profile of next-generation versions of the drugs now on the market. We believe this strategy of targeting drugs with proven safety and efficacy allows us to lower the risk profile of our proprietary development portfolio as compared to de novo protein drug development.
Our proprietary drug development portfolio currently consists of two therapeutic protein candidates. GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and is approved for sale in major markets around the world for treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Our second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor (G-CSF) that we are co-developing with BioGeneriX AG, a company of the ratiopharm Group. G-CSF is prescribed to stimulate production of neutrophils (a type of white blood cell) and is approved for sale in major markets around the world for treatment of neutropenia associated with myelosuppressive chemotherapy. .
